GSK / 221530

Official Title

A Randomized, Double-blind, Placebo-controlled Phase 3 Study to evaluate Dostarlimab as Sequential Therapy after Chemoradiation in Participants with Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

Study Purpose

To evaluate the efficacy of dostarlimab as sequential therapy following CRT as compared to placebo in participants with PD-L1 positive LA unresected HNSCC

 

Diagnosis

Newly diagnosed unresected locally advanced head and neck squamous cell carcinoma (Stages III-IVB)

Eligibility

Newly diagnosed unresected locally advanced squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx, and completed cisplatin plus radiotherapy, and has no evidence of distant metastatic disease.

 

Intervention

Dostarlimab vs. Placebo